Loading clinical trials...
Loading clinical trials...
A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events with Oral Colchicine 0.5mg Once Daily Compared with Placebo in Participants with Spontaneous ICH and Established, or Risk Factors For, Atherosclerosis
Conditions
Interventions
Colchicine Pill
Placebo
Locations
11
Canada
University of Calgary, Foothills Medical Centre
Calgary, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
Hamilton General Hospital, Hamilton Health Sciences
Hamilton, Ontario, Canada
Kingston General Hospital, Kingston Health Sciences
Kingston, Ontario, Canada
London Health Science Centre, University Hospital
London, Ontario, Canada
Start Date
August 4, 2022
Primary Completion Date
December 3, 2024
Completion Date
December 3, 2024
Last Updated
January 16, 2025
NCT07088250
NCT06320132
NCT05968053
NCT05298436
NCT04337697
NCT07338383
Lead Sponsor
Population Health Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions